These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
195 related articles for article (PubMed ID: 31755287)
21. Why Colchicine Should Be Considered for Secondary Prevention of Atherosclerosis: An Overview. Nidorf SM; Thompson PL Clin Ther; 2019 Jan; 41(1):41-48. PubMed ID: 30591286 [TBL] [Abstract][Full Text] [Related]
22. Canakinumab: Promises and Future in Cardiometabolic Diseases and Malignancy. Dhorepatil A; Ball S; Ghosh RK; Kondapaneni M; Lavie CJ Am J Med; 2019 Mar; 132(3):312-324. PubMed ID: 30832770 [TBL] [Abstract][Full Text] [Related]
23. Cholesterol-embolization syndrome: current perspectives. Ozkok A Vasc Health Risk Manag; 2019; 15():209-220. PubMed ID: 31371977 [TBL] [Abstract][Full Text] [Related]
24. Residual inflammatory risk associated with interleukin-18 and interleukin-6 after successful interleukin-1β inhibition with canakinumab: further rationale for the development of targeted anti-cytokine therapies for the treatment of atherothrombosis. Ridker PM; MacFadyen JG; Thuren T; Libby P Eur Heart J; 2020 Jun; 41(23):2153-2163. PubMed ID: 31504417 [TBL] [Abstract][Full Text] [Related]
27. Curcumin suppresses NLRP3 inflammasome activation and protects against LPS-induced septic shock. Gong Z; Zhou J; Li H; Gao Y; Xu C; Zhao S; Chen Y; Cai W; Wu J Mol Nutr Food Res; 2015 Nov; 59(11):2132-42. PubMed ID: 26250869 [TBL] [Abstract][Full Text] [Related]
28. Targeting Inflammation and Immune System in Acute Myocardial Infarction. Alwi I Acta Med Indones; 2019 Oct; 51(4):287-289. PubMed ID: 32041910 [TBL] [Abstract][Full Text] [Related]
29. From CANTOS to CIRT to COLCOT to Clinic: Will All Atherosclerosis Patients Soon Be Treated With Combination Lipid-Lowering and Inflammation-Inhibiting Agents? Ridker PM Circulation; 2020 Mar; 141(10):787-789. PubMed ID: 32150469 [No Abstract] [Full Text] [Related]
31. Targeting IL-1beta in disease; the expanding role of NLRP3 inflammasome. Mitroulis I; Skendros P; Ritis K Eur J Intern Med; 2010 Jun; 21(3):157-63. PubMed ID: 20493414 [TBL] [Abstract][Full Text] [Related]
32. From pathophysiology to targeted therapy for atherothrombosis: a role for the combination of statin and aspirin in secondary prevention. Chapman MJ Pharmacol Ther; 2007 Jan; 113(1):184-96. PubMed ID: 17070923 [TBL] [Abstract][Full Text] [Related]
33. NLRP3 Inflammasome Expression and Activation in Human Atherosclerosis. Paramel Varghese G; Folkersen L; Strawbridge RJ; Halvorsen B; Yndestad A; Ranheim T; Krohg-Sørensen K; Skjelland M; Espevik T; Aukrust P; Lengquist M; Hedin U; Jansson JH; Fransén K; Hansson GK; Eriksson P; Sirsjö A J Am Heart Assoc; 2016 May; 5(5):. PubMed ID: 27207962 [TBL] [Abstract][Full Text] [Related]
34. Expression of the NLRP3 Inflammasome in Carotid Atherosclerosis. Shi X; Xie WL; Kong WW; Chen D; Qu P J Stroke Cerebrovasc Dis; 2015 Nov; 24(11):2455-66. PubMed ID: 26381780 [TBL] [Abstract][Full Text] [Related]
39. Development of anti-atherosclerosis therapy based on the inflammatory and proliferative aspects of the disease. Maranhão RC; Leite AC Curr Pharm Des; 2015; 21(9):1196-204. PubMed ID: 25312729 [TBL] [Abstract][Full Text] [Related]
40. NLRP3 inflammasome: Its regulation and involvement in atherosclerosis. Hoseini Z; Sepahvand F; Rashidi B; Sahebkar A; Masoudifar A; Mirzaei H J Cell Physiol; 2018 Mar; 233(3):2116-2132. PubMed ID: 28345767 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]